Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O6-benzylguanine and topical carmustine in refractory early-stage CTCL
NCT00961220Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2010
- Primary completion
- Apr 2012
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in cutaneous T-cell lymphoma (CTCL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Feb 2010; status: completed.
02
Drugs
6-benzylguanine
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00961220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961220.